AI Execution Engine From Building An AI Tools To Selling Experience

Anyone can ask AI for an explanation, a checklist, ideas or “10 steps”. The bigger opportunity is a focused experience that already knows the job: what inputs to collect, what knowledge to use, what process to follow, what result to produce and what should happen next. “Here is the information. Now figure out how it applies to you.”

• Your course, PDF or framework holds the answer
• Each buyer works out how it applies to them
• Great content, and the next step is up to them

No developers. No prompt engineering. You describe the job, and AIEE runs it. When you’re ready to sell, the inEight kinds of tools and 24 ready-to-copy ideas, so every market can spot itself. Every one of them can be built in AIEE. Which one would you build first?rastructure is already there. Don’t think “AI app”. Think product: a digital product you build once and people use again and again.

Don’t just make videos. Build the tool that makes them: a faceless shorts maker, a product promo generator, a listing teaser tool. Your buyers run it, your name is on it. Powered by Veo 3, Kling and Seedance. “Upload your anything, get it scored.” People will pay to have their own work reviewed, and your tool reviews it using your criteria.

Thumbnails, logos, product mock-ups and social graphics. Image generation with OpenAI or Google Nano Banana, wrapped in a tool that knows your niche. These tools search the live web and give answers with cited sources. That’s research people would otherwise pay a freelancer for. A few answers in, a finished, downloadable PDF out. These are plans, reports and proposals people are used to paying for.

A few answers in, a finished, downloadable PDF out. These are plans, reports and proposals people are used to paying for. Tools that help your market sell more of what they already have: offers, lead magnets, bonuses and recommendations. Tools that help customers get started, get answers and keep coming back. Sell it, give it away, bundle it, or plug it into the business you already have. Here’s what each one looks like, with an example tool you could build this week.

Every AIEE Engine included with your account comes with full commercial rights. Build Engines for your own business, sell access to them, use them with your customers, students or members, or get paid to build custom AIEE Engines for clients as a freelancer, consultant, coach or service provider. You’re not limited to experimenting with AI behind the scenes. You can actually put your Engines to work in a real business…..

Source: AI Execution Engine

.

AIToolMaker ,AIDesign ,DigitalInnovation ,TechSolutions ,MachineLearning ,AIApplications ,SmartTechnology ,#CreativityWithAI ,InnovationUnleashed ,AIForBusiness ,TechTrends ,NextGenAI ,ArtificialIntelligence ,ExperienceAI ,FutureOfTech ,TechInspiration ,AIDevelopment ,Automation ,AICommunities

Share this:

• More

Customize buttons

Leave a Reply

marketingscoopsEdit profileLog out

Previous Post
El Nino Breaks Pacific Temperature Record As Weather Pattern Intensifies 

Medicine Needs To Get Serious About AI

Illustration by The Atlantic. Source: Getty.

For as long as ChatGPT has existed, Americans have been asking it, “Could that funny little spot on my toe be cancer?” And as AI has advanced over the past few years, doctors have begun to use specialized models to ask much the same questions in clinics. In the face of these developments, professional medical societies have presented a unified front: Doctors must always have the final say in clinical care. We disagree. As the medical societies allow, physicians’ enhancing their work with AI tools may be a perfectly good way to deliver medicine. But for Americans to get the best health care possible, we need to be willing to experiment with models that put AI in control…….Continue reading…

By: Ezekiel J. Emanuel and Vinod Kholsa

Source: The Atlantic

.

Critics:

Medical training needs to change immediately so human doctors can focus on what they uniquely provide—like ethical reasoning, physical touch, and complex human empathy—rather than acting as slower, less efficient “instruments in a white coat”. A major point of friction highlighted in the JAMA and Atlantic papers is the warning that poorly integrated human-AI hybrids can actually degrade performance.

When doctors blindly trust or incorrectly override automated systems, errors increase. Medicine needs rigorous protocols to determine exactly when autonomous models should work independently. Data from the American Medical Association (AMA) shows that over 80% of physicians now use some form of AI in their daily practice, a massive jump from just 38% a few years prior.

Hospital networks are heavily implementing ambient AI scribes from companies like Nuance, Abridge, and Nabla to tackle documentation burdens and clinician burnout. Institutions like Johns Hopkins Medicine are already deploying fully autonomous FDA-cleared AI to screen adult and pediatric patients for diabetic eye disease, successfully expanding access and equity.The overarching takeaway from the current debate is clear:

AI cannot replace the ultimate accountability of a human clinician, but the medical field can no longer afford to treat AI as a futuristic luxury.

What STAT readers think about M.D. vs. D.O., AI in medicine, surrogacy, and more  12:08 Sat, 05 Sep 

AI Could Revolutionize Medicine, But Humans Must Be in Charge: Researcher Shreya Johri  18:19 Thu, 03 Sep 

Nuffield Department of Medicine at the University of Oxford and 2U Launch New Program in AI-Driven Drug Discovery  17:34 Thu, 03 Sep 

Insilico Medicine Included in the Hkex Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain  04:04 Thu, 03 Sep 

Insilico Medicine Convenes O3DC, An Open Consortium For Benchmark Quality In AI-Driven Drug Discovery  13:10 Thu, 27 Aug 

AMA introduces Ethical AI Use in Medicine Series  19:50 Wed, 26 Aug 

The Benefits and Challenges of AI in Transfusion Medicine  17:32 Mon, 17 Aug 

The Most Important Thing AI Can’t Do in Medicine  13:36 Sat, 15 Aug 

AI-Empowered Pipeline-In-A-Drug Option: Insilico Medicine Nominates ISM9077, Potential First-In-Class Target Y Inhibitor, As Preclinical Candidate (PCC) For Ocular Diseases, Inflammatory Disorders And Aging 11:22 Thu, 13 Aug 

.

AIinMedicine ,HealthTech ,MedicalInnovation ,HealthcareAI ,ArtificialIntelligence ,FutureOfMedicine ,MedTech ,AIApplications ,DigitalHealth ,SmartHealthcare ,HealthAI ,MachineLearningInHealth ,ClinicalAI ,MedTechInnovation ,DataScienceInHealth ,PrecisionMedicine ,HealthData ,AIHealing ,TechInHealthcare

Share this:

• More

Customize buttons

Leave a Reply

Write a comment...

Previous Post
Blockchain Forensics Explained: Combatting Illicit Activity On-Chain